Glioblastoma Clinical Trials 2024

What are the top hospitals conducting glioblastoma research?

When it comes to pioneering clinical trials for glioblastoma, several top hospitals are making significant strides in this challenging field. In Boston, the Dana-Farber Cancer Institute leads the way with 11 active trials dedicated to tackling this aggressive brain cancer. With a remarkable history of 65 completed glioblastoma trials since their first recorded effort in 1998, they have been at the forefront of breakthrough research. Meanwhile, Memorial Sloan Kettering Cancer Center in New York is also making notable contributions with eight ongoing glioblastoma trials and an impressive track record of 47 previous studies dating back to their initial trial in 2002.

Moving westward to Saint Louis, the Washington University School of Medicine has emerged as another key player in glioblastoma research. With eight active clinical trials and a history of 49 past investigations since their first recorded trial in 2006, they are pushing boundaries and seeking innovative solutions for this devastating disease. Closer to home on the East Coast, Lenox Hill Brain tumor Center in New York boasts five ongoing clinical trials focused on glioblastoma along with a total of fifteen previously conducted studies since their groundbreaking trial's initiation back in 2006.

Finally arriving on the West Coast at San Francisco's esteemed University of California site; here too researchers are dedicating efforts towards confronting this complex brain tumor type through five robust active clinical experiments while having delved into twenty-five prior trials; all initiated from recording its inaugural investigation concerning such cases just around two decades ago (in early-2004).

These leading hospitals not only demonstrate unwavering commitment but serve as beacons of hope for those affected by glioblastoma. Their collaborative efforts highlight the tireless pursuit for advancements that hold potential life-changing impacts on patients' lives worldwide combating this formidable condition

Which are the best cities for glioblastoma clinical trials?

When it comes to glioblastoma clinical trials, several cities have emerged as prominent centers of research and innovation. New york, with 32 active trials, investigates treatments such as INO-5401, Pemigatinib, RT plus TMZ and ENZ among others. Boston follows closely behind with 29 ongoing studies focusing on therapies like Pembrolizumab and Olaparib. Saint Louis boasts 21 active trials examining interventions including Quality-of-Life Assessment and Radiation Therapy. Additionally, Los Angeles contributes significantly to the field with 18 ongoing trials exploring various treatment combinations involving RT plus TMZ and ENZ along with Adavosertib and Surgery approaches. Lastly, Dallas showcases its commitment to advancing care for glioblastoma patients through 16 active trials studying treatments like Pemigatinib and Sacituzumab Govitecan. These cities serve as beacons of hope for individuals battling this aggressive form of brain cancer by providing access to cutting-edge clinical trials that pave the way for improved outcomes in the future.

Which are the top treatments for glioblastoma being explored in clinical trials?

Glioblastoma, a formidable foe in the realm of brain cancers, is currently being tackled by cutting-edge treatments under exploration in clinical trials. Temozolomide emerges as a frontrunner with its involvement in six active trials and an impressive track record of 218 all-time glioblastoma studies since its debut in 2002. Nivolumab follows closely behind with three ongoing trials and 27 all-time glioblastoma investigations that began back in 2014. Additionally, radiation therapy commands attention with three active trials and a solid foundation of 48 all-time glioblastoma research efforts dating back to 2004. Two other contenders making strides include intra-arterial cetuximab and Ibrutinib, each involved in two active trials contributing to the limited but growing body of knowledge surrounding their potential effectiveness against this challenging cancer type.

What are the most recent clinical trials for glioblastoma?

Recent advancements in clinical trials offer hope for glioblastoma patients, with several promising studies underway. One such trial is examining the efficacy of autologous therapy in treating glioblastoma through a Phase 1 and Phase 2 Arm A approach. Another study focuses on Group A dose escalation as a potential treatment option for this aggressive brain tumor. Additionally, there are ongoing investigations into newly diagnosed glioblastoma participants to explore innovative therapies. With Stratum A trials and research on combining standard surgical treatment with intraoperative electrocorticography also making progress, these developments bring optimism to individuals battling glioblastoma.

What glioblastoma clinical trials were recently completed?

Numerous clinical trials for glioblastoma have recently concluded, showcasing the continuous efforts to combat this challenging brain cancer. In May 2021, Washington University School of Medicine completed a trial evaluating the potential of Tadalafil as a treatment option. Further back in January 2021, Kiarash Shahlaie, M.D., Ph.D., sponsored a Lidocaine trial that reached completion. Other notable studies include GLR2007 by Gan and Lee Pharmaceuticals in July 2020, Carboplatin by CarThera in February 2019, LB-100 by the National Cancer Institute (NCI) in January 2019, and Ribociclib by St. Joseph's Hospital and Medical Center in December 2018. These trials contribute valuable insights to advance our understanding of glioblastoma treatment options.